Page 49 - IMO-2-2

Innovative Medicines & Omics Alzheimer’s disease and clinical trials

rates continuing to increase over the years. Moreover, doi: 10.1002/ana.21706
individuals with dementia require lifelong caregiving. 4. Schneider JA, Arvanitakis Z, Bang W, Bennett DA.
These diseases demand urgent attention to develop Mixed brain pathologies account for most dementia
effective preventive and curative treatments. Through cases in community-dwelling older persons. Neurology.
in-depth research, innovative drug design, and systematic 2007;69:2197-2204.
clinical trials, the discovery of effective treatments for AD doi: 10.1212/01.wnl.0000271090.28148.24
and RD may become a reality in the near future.
5. Kawas CH, Kim RC, Sonnen JA, Bullain SS, Trieu T,
Acknowledgments Corrada MM. Multiple pathologies are common and related
to dementia in the oldest-old: The 90 study. Neurology.
+
None. 2015;85:535-542.
Funding doi: 10.1212/WNL.0000000000001831
None. 6. Singh AS, Chanu MT. Alzheimer’s disease and Aβ pathways.
World J Adv Res Rev. 2021;12:542-544.
Conflict of interest doi: 10.30574/wjarr.2021.12.3.0740
Asem Surindro Singh and Machathoibi Takhellambam 7. Li X, Feng X, Sun X, Hou N, Han F, Liu Y. Global, regional, and
Chanu are the guest editors of this special issue but were national burden of Alzheimer’s disease and other dementias,
not in any way involved in the editorial and peer-review 1990-2019. Front Aging Neurosci. 2022;14:937486.
processes conducted for this paper, directly or indirectly. doi: 10.3389/fnagi.2022.937486
Separately, other authors declared that they have no known 8. Rajan KB, Weuve J, Barnes LL, McAninch EA, Wilson RS,
competing financial interests or personal relationships that Evans DA. Population estimate of people with clinical
could have influenced the work reported in this paper. Alzheimer’s disease and mild cognitive impairment
Author contributions in the United States (2020-2060). Alzheimers Dement.
2021;17:1966-1975.
Conceptualization: Asem Surindro Singh, Machathoibi doi: 10.1002/alz.12362
Takhellambam Chanu
Writing – original draft: Asem Surindro Singh, Machathoibi 9. Singh AS, Chanu MT. Alzheimer’s disease and related
dementia drug trials, failures and progress: Data update
Takhellambam Chanu 2024. Preprint. 2024.
Writing – review & editing: All authors
doi: 10.20944/preprints202412.2518.v1
Ethics approval and consent to participate 10. Singh AS, Chanu MT. Epigenetic regulation of

Not applicable. neuroinflammation leading to dementia of Alzheimer’s
disease and other forms of dementias. Preprint. 2024.
Consent for publication doi: 10.20944/preprints202412.2476.v1

Not applicable. 11. Singh AS, Chanu MT. Microglial, Astrocytic,
oligodendrocytic, T-Cell and B-cell inflammatory pathways
Availability of data underlying cognitive impairment in Alzheimer’s disease and
Not applicable. related dementias. Preprint. 2024.
doi: 10.20944/preprints202412.2427.v1
References
12. Friedman EM, Shih RA, Langa KM, Hurd MD. US prevalence
1. 2024 Alzheimer’s disease facts and figures. Alzheimers and predictors of informal caregiving for dementia. Health
Dement. 2024;20:3708-3821. Aff (Millwood). 2015;34:1637-1641.
doi: 10.1002/alz.13809 doi: 10.1377/hlthaff.2015.0510
2. 2023 Alzheimer’s disease facts and figures. Alzheimers 13. Jutkowitz E, Kane RL, Gaugler JE, MacLehose RF, Dowd B,
Dement. 2023;19:1598-1695. Kuntz KM. Societal and family lifetime cost of dementia:
Implications for policy. J Am Geriatr Soc. 2017;65:2169-2175.
doi: 10.1002/alz.13016
doi: 10.1111/jgs.15043
3. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The
neuropathology of probable Alzheimer disease and mild 14. Tatulian SA. Challenges and hopes for Alzheimer’s disease.
cognitive impairment. Ann Neurol. 2009;66:200-208. Drug Discov Today. 2022;27:1027-1043.

Volume 2 Issue 2 (2025) 43 doi: 10.36922/IMO025050007